The role of epidemiology in challenging the HIV/AIDS pandemic
- PMID: 11388499
- PMCID: PMC11638027
- DOI: 10.2188/jea.11.95
The role of epidemiology in challenging the HIV/AIDS pandemic
Abstract
The HIV/AIDS pandemic has challenged the resourcefulness of epidemiology and epidemiologists. In response to the challenge, epidemiologists have used existing epidemiologic strategies, expanded existing strategies, and developed new strategies to answer key questions about the transmission of HIV, the natural history of HIV at the molecular, host, and community levels, for evaluation of treatment effectiveness and intervention strategies, and to inform public health policy. In responding to the challenge of the pandemic, epidemiologists have also increasingly collaborated with scientists from other disciplines, particularly immunology, virology, and the behavioral sciences. Examples of the application of these epidemiologic strategies are presented.
Figures
References
-
- Joint United Nations Programme on HIV/AIDS (UNAIDS) and the World Health Organization (WHO) website: http://www.unaids.org/wac/2000/wad00/files/wad2000 Master/sld003. htm
-
- Detels R, Phair JP, Saah AJ, Rinaldo CR, Munoz A, Kaslow RA, Seminara D, Schrager L, Vermund S. Recent scientific contributions to understanding HIV/AIDS from the Multicenter AIDS Cohort Study. J Epidemiol [Jpn] 1992; 2(2): S11-S19.
-
- Detels R, English P, Visscher BR, Jacobson L, Kingsley LA, Chmiel JS, Dudley JP, Eldred LJ, Ginzburg HM. Seroconversion, sexual activity, and condom use among 2915 HIV seronegative men followed for up to 2 years. J Acquir Immune Defic Syndr 1989; 2: 77-83. - PubMed
-
- Munoz A, Sabin CA, Phillips AN. The incubation period of AIDS. AIDS 1997; 11 (Suppl A): S69-S76. - PubMed
-
- Detels R, Mann D, Carrington M, Hennessey K, Wu Z, Hirji KF, Wiley D, Visscher BR, Giorgi JV. Persistently seronegative men from whom HIV-1 has been isolated are genetically and immunologically distinct. Immunol Lett 1996; 51: 29-33. - PubMed
Publication types
MeSH terms
Grants and funding
- U01 AI035042/AI/NIAID NIH HHS/United States
- U01 AI037984/AI/NIAID NIH HHS/United States
- UO1-AI-35042/AI/NIAID NIH HHS/United States
- K01 TW000013/TW/FIC NIH HHS/United States
- UO1-AI35040/AI/NIAID NIH HHS/United States
- U01 AI035041/AI/NIAID NIH HHS/United States
- U01 AI035043/AI/NIAID NIH HHS/United States
- UO1-AI-35039/AI/NIAID NIH HHS/United States
- U01 AI035040/AI/NIAID NIH HHS/United States
- D43 TW000013/TW/FIC NIH HHS/United States
- U01 AI035039/AI/NIAID NIH HHS/United States
- UO1-AI-37984/AI/NIAID NIH HHS/United States
- 5-M01-RR-00052/RR/NCRR NIH HHS/United States
- U01 AI037613/AI/NIAID NIH HHS/United States
- UO1-AI-35041/AI/NIAID NIH HHS/United States
- TW00013/TW/FIC NIH HHS/United States
- M01 RR000052/RR/NCRR NIH HHS/United States
- UO1-AI-35043/AI/NIAID NIH HHS/United States
- UO1-AI-37613/AI/NIAID NIH HHS/United States
